

VISUtein™ improves visual parameters in Age-Related Macula Degeneration
and outperforms the leading brand of eye supplement on the market

Orem, UT – November 24th 2006 – for immediate release.

Unicity International's leading vision product, VISUtein™, has been studied in a double-blind, controlled study, involving patients with age-related macula degeneration, or AMD. The study was performed by Dr. David Newsome, director of the Louisiana Retinal Institute. AMD leads the causes of untreatable visual loss and legal blindness among persons 65 years old or older in the United States and other countries. It is believed that oxidative stress inflicted to the retina plays a major role in the etiology of AMD, as well as declining lutein and zeaxanthin concentrations in the macula, also known as yellow spot. Recently, the AREDS study, sponsored by the National Eye Institute, proved that a combination of zinc, vitamins E, and C and beta carotene may delay the progression of AMD. Several companies are marketing the exact product that was studied in the AREDS study. Since the onset of the study, however, new science has emerged that has identified other dietary ingredients that are important to preserve eye sight in AMD. VISUtein™ is the only product on the market today that combines the latest scientifically proven ingredients. Apart from the AREDS ingredients, VISUtein™ features lutein and zeaxanthin, two carotenoids that are known to be vital for the correct functioning of the retina, and that are removed from the macula during AMD. Moreover, VISUtein™ provides N-acetyl cysteine, a precursor for glutathione, which known to be a very powerful antioxidant, in particular for the retinal tissue.

In the current study, Dr. Newsome tested VISUtein™ in a group of 35 subjects with established AMD. Eighteen of the subjects received VISUtein™ for a period of 6 months. The remaining 17 subjects used a competitive product called OcuVite, which is based entirely on the AREDS formulation. All subjects had follow up visits at 3 and 6 months. Parameters tested were visual acuity, contrast

sensitivity, and recovery from a flash. The study group receiving the OcuVite showed no functional loss during the six months and a slight improvement in photo recovery times. The VISUtein™ group showed improvement in all parameters tested over the 6 months period. Moreover, there were clear significant differences between the two groups for all parameters, in favor of VISUtein™. This study has proven that VISUtein™, providing complete nutritional care for AMD patients, may improve visual parameters, and outperforms the leading commercial brand of vision nutritionals. The study is currently under consideration for publication in a peer-reviewed journal.

For further information, please contact Annmarie Waite at:
annmarie@girlfriendshealth.com or (321) 984-7667.